Skip to Main content Skip to Navigation
Journal articles

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate

A. Senchyna S. Simon H. Cissé M. Ginouves Ghislaine Prevot 1, 2 G. Alcoba Magalie Pierre Demar P. Couppie R. Blaizot
2 TBIP - Tropical Biome and ImmunoPathophysiology
Université Lille Nord de France (COMUE), Institut Pasteur de Lille, INSERM - Institut National de la Santé et de la Recherche Médicale, UG - Université de Guyane, CHRU Lille - Centre Hospitalier Régional Universitaire [Lille], CNRS - Centre National de la Recherche Scientifique
Abstract : New World cutaneous leishmaniasis (CL) is endemic in many countries of Latin America, including French Guiana 1. While pentamidine is the first‐line treatment against Leishmania guyanensis in this territory 2, pentavalent antimonials such as meglumine antimoniate (MA) are recommended in case of L. braziliensis or pentamidine‐resistant strains of other species 2. Liposomal amphotericin B (L‐AmB) (Ambisome ®) is widely used against fungi and visceral leishmaniasis 3. However, data concerning its efficacy in New World CL are scarce and contradictory 4‐7. Due to a shortage in MA, the Cayenne Hospital started using L‐AmB as an alternative in 2015. We conducted a retrospective study to compare efficacy and safety of L‐AmB and MA in patients treated for CL.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-guyane.fr/hal-03282671
Contributor : Mirlène Matillon Connect in order to contact the contributor
Submitted on : Friday, July 9, 2021 - 12:53:50 PM
Last modification on : Thursday, September 30, 2021 - 8:46:02 PM

Links full text

Identifiers

Collections

Citation

A. Senchyna, S. Simon, H. Cissé, M. Ginouves, Ghislaine Prevot, et al.. American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate. British Journal of Dermatology, Wiley, 2020, 183 (2), pp.389-391. ⟨10.1111/bjd.18964⟩. ⟨hal-03282671⟩

Share

Metrics

Record views

26